UBS Maintains Buy on Cardinal Health, Raises Price Target to $274

Benzinga Newsdesk www.benzinga.com Positive 85.5%

Neg 0% Neu 0% Pos 85.5%

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:CAH) with a Buy and raises the price target from $260 to $274.